MX2009007548A - Derivados de glicina n-sustituidos: inhibidores de hidroxilasa. - Google Patents

Derivados de glicina n-sustituidos: inhibidores de hidroxilasa.

Info

Publication number
MX2009007548A
MX2009007548A MX2009007548A MX2009007548A MX2009007548A MX 2009007548 A MX2009007548 A MX 2009007548A MX 2009007548 A MX2009007548 A MX 2009007548A MX 2009007548 A MX2009007548 A MX 2009007548A MX 2009007548 A MX2009007548 A MX 2009007548A
Authority
MX
Mexico
Prior art keywords
substituted glycine
glycine derivatives
hydroxylase inhibitors
derivatives
substituted
Prior art date
Application number
MX2009007548A
Other languages
English (en)
Spanish (es)
Inventor
Kevin J Duffy
Antony N Shaw
William Henry Miller
Andrea K Myers
Michael N Zimmerman
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39636631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX2009007548A publication Critical patent/MX2009007548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009007548A 2007-01-12 2008-01-11 Derivados de glicina n-sustituidos: inhibidores de hidroxilasa. MX2009007548A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88471007P 2007-01-12 2007-01-12
PCT/US2008/050833 WO2008089052A2 (en) 2007-01-12 2008-01-11 N-substituted glycine derivatives: hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
MX2009007548A true MX2009007548A (es) 2009-07-22

Family

ID=39636631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007548A MX2009007548A (es) 2007-01-12 2008-01-11 Derivados de glicina n-sustituidos: inhibidores de hidroxilasa.

Country Status (20)

Country Link
US (2) US7608621B2 (https=)
EP (2) EP2124565B1 (https=)
JP (1) JP5313925B2 (https=)
KR (1) KR101458655B1 (https=)
CN (1) CN101626685B (https=)
AR (1) AR064878A1 (https=)
AU (1) AU2008206441B2 (https=)
BR (1) BRPI0806566A2 (https=)
CA (1) CA2675252C (https=)
CL (1) CL2008000066A1 (https=)
DK (1) DK2124565T3 (https=)
EA (1) EA017112B1 (https=)
ES (2) ES2528745T3 (https=)
HR (1) HRP20150119T1 (https=)
MX (1) MX2009007548A (https=)
PL (1) PL2124565T3 (https=)
PT (1) PT2124565E (https=)
SI (1) SI2124565T1 (https=)
TW (1) TW200845991A (https=)
WO (1) WO2008089052A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI336260B (en) * 2002-07-25 2011-01-21 Glaxo Group Ltd Dosage form suitable for retaining drug substance
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
ITMI20051085A1 (it) * 2005-06-10 2006-12-11 Acs Dobfar Spa Metodo di purificazione del cefotetan
US8450351B2 (en) * 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036642A2 (en) * 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
WO2010025087A1 (en) * 2008-08-25 2010-03-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2010055884A1 (ja) * 2008-11-13 2010-05-20 日本農薬株式会社 ピラジン誘導体類の製造方法及びその中間体類
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
DE102009004061A1 (de) * 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
KR101665749B1 (ko) * 2009-10-21 2016-10-12 다이이찌 산쿄 가부시키가이샤 5-하이드록시피리미딘-4-카르복사미드 유도체
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
WO2011115687A2 (en) * 2010-03-19 2011-09-22 Northwestern University Alkylated sp-b peptoid compounds and related lung surfactant compositions
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (https=) 2011-06-06 2018-03-17
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013063221A1 (en) 2011-10-25 2013-05-02 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
TWI583670B (zh) 2012-07-30 2017-05-21 大正製藥股份有限公司 Partially saturated nitrogenous heterocyclic compounds
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
ES2799582T3 (es) 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
WO2021127273A1 (en) * 2019-12-20 2021-06-24 Gb004, Inc. 1 -((6-oxo-1,6-dihydropyridazin-4-yl)methyl)piperazine and 1 -((6-oxo-1,6-dihydropyrimidin-4-yl)methyl)piperazine derivatives as prolyl hydroxylase, hif-1 alpha and pgk modulators for use in treating inflammatory diseases, cancer or infections
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149485T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
AU2003225088A1 (en) 2002-04-19 2003-11-03 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
WO2008040002A2 (en) 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands

Also Published As

Publication number Publication date
USRE44613E1 (en) 2013-11-26
ES2614355T3 (es) 2017-05-30
US20080214549A1 (en) 2008-09-04
AU2008206441A1 (en) 2008-07-24
CN101626685A (zh) 2010-01-13
JP2010515756A (ja) 2010-05-13
SI2124565T1 (sl) 2015-04-30
US7608621B2 (en) 2009-10-27
EP2124565B1 (en) 2015-01-07
PT2124565E (pt) 2015-03-26
AR064878A1 (es) 2009-04-29
BRPI0806566A2 (pt) 2014-05-06
EP2889289A1 (en) 2015-07-01
CL2008000066A1 (es) 2008-08-01
WO2008089052A2 (en) 2008-07-24
EA200970680A1 (ru) 2010-02-26
EP2889289B1 (en) 2016-12-21
KR20090101376A (ko) 2009-09-25
KR101458655B1 (ko) 2014-11-05
HRP20150119T1 (hr) 2015-05-08
EA017112B1 (ru) 2012-09-28
EP2124565A2 (en) 2009-12-02
EP2124565A4 (en) 2011-06-29
JP5313925B2 (ja) 2013-10-09
CN101626685B (zh) 2013-03-13
CA2675252C (en) 2015-05-26
DK2124565T3 (en) 2015-02-09
PL2124565T3 (pl) 2015-05-29
ES2528745T3 (es) 2015-02-12
TW200845991A (en) 2008-12-01
AU2008206441B2 (en) 2014-06-19
CA2675252A1 (en) 2008-07-24
WO2008089052A3 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
MX2009007548A (es) Derivados de glicina n-sustituidos: inhibidores de hidroxilasa.
MY149861A (en) Prolyl hydroxylase inhibitors
WO2009073497A3 (en) Prolyl hydroxylase inhibitors
WO2007103905A3 (en) Prolyl hydroxylase inhibitors
WO2007136990A3 (en) Prolyl hydroxylase inhibitors
WO2010022307A3 (en) Prolyl hydroxylase inhibitors
EA201000920A1 (ru) Ингибиторы пролилгидроксилазы
MX2009000884A (es) Derivados de piridizinona.
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
HRP20130797T1 (en) Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
TW200640924A (en) VEGF-R2 inhibitors and methods
MX2010010209A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
EA201100687A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
MX2007008555A (es) Amino-imidazolonas para la inhibicion de (-secretasa.
MX2008000017A (es) Derivados de isoquinolina como inhibidores de rho-cinasa.
UA105000C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration